Rapidly increasing off-label use of rituximab in multiple sclerosis in Sweden - Outlier or predecessor?

S G Berntsson, A Kristoffersson,I Boström, A Feresiadou,J Burman,A M Landtblom

Acta neurologica Scandinavica（2018）

引用 39|浏览12

暂无评分

摘要

The share of MS patients in Sweden who are treated with rituximab is very high, and also rapidly increasing. Taken into account the off-label use, cases with adverse medical conditions that could possibly be related to rituximab use should be reported thoroughly.

查看译文

关键词

adverse events,immunomodulatory drugs,multiple sclerosis,off-label prescription,pharmacotherapy,rituximab side effects

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要